🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: GSK573719 125

Found 20 matching trials

To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)

PHASE1

This will be a randomized, double-blind, single-dose, three-period balanced...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-11-08

Trial ID

NCT01725685

Treatments Being Tested

FF 400 mcg UMEC 500 mcg FF/UMEC 400/500 mcg

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

PHASE1

This study will evaluate the pharmacokinetics of FF, UMEC and VI administer...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-07-15

Trial ID

NCT01894386

Treatments Being Tested

FF 400 mcg UMEC 500 mcg UMEC 250 mcg VI 100 mcg

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A

PHASE3

This is a phase III multicenter, randomized, double-blind, placebo-controll...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-01

Trial ID

NCT01328444

Treatments Being Tested

GSK 573719 +GW642444 125/25 GSK573719 + GW642444 62.5/25 GSK 573719 125 GSK 573719 62.5 GW642444 25 Plb

A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

The purpose of this study is to further characterize the dose response of G...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-07-01

Trial ID

NCT01372410

Treatments Being Tested

GSK573719 GSK573719 GSK573719 GSK573719 GSK573719 GSK573719 Tiotropium Placebo

Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler.

PHASE1

GSK573719 is a high-affinity specific muscarinic receptor (mAChR) antagonis...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-10-12

Trial ID

NCT01521390

Treatments Being Tested

GSK573719 62.5 mcg (one strip)GSK573719 62.5 mcg(two strips)GSK573719 125 mcg (one strip)GSK573719 125 mcg(two strips)Placebo

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B

PHASE3

This is a phase III multicenter, randomized, double-blind, placebo-controll...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-16

Trial ID

NCT01323660

Treatments Being Tested

GSK573719/GW642444 125/25 GSK573719/GW642444 62.5/25 GSK573719 125 GSK573719 62.5 GW642444 25 placebo

24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease

PHASE3

This is a Phase III multicenter, randomized, double-blind, double-dummy, pa...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-01

Trial ID

NCT01316900

Treatments Being Tested

GSK573719/GW642444 125/25 GSK573719/GW642444 62.5/25 GW642444 tiotropium bromide

Long-term Safety Study for GSK573719 in Japanese

PHASE3

The objective of this study is to evaluate the safety and tolerability of G...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-08

Trial ID

NCT01702363

Treatments Being Tested

GSK573719

A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The purpose of this 52-week study is to evaluate the long-term safety (in t...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-01-01

Trial ID

NCT01316887

Treatments Being Tested

125/25 mcg once-daily GSK573719/GW642444 125mcg once-daily GSK573719 Placebo once-daily

A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma

PHASE2

This is a multi-national, randomized, double-blind, 3-period crossover, inc...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-05

Trial ID

NCT01641692

Treatments Being Tested

GSK573719 Active treatment or Placebo GSK573719 (Sub-group cohort)Salbutamol/Albuterol

Previous Next